Insider Transactions in Q1 2023 at Kal Vista Pharmaceuticals, Inc. (KALV)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 17
2023
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,954
-6.37%
|
$34,678
$7.66 P/Share
|
|
Feb 17
2023
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,363
+10.75%
|
-
|
|
Feb 17
2023
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,727
-7.09%
|
$19,089
$7.66 P/Share
|
|
Feb 17
2023
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,204
+9.86%
|
-
|
|
Feb 17
2023
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,228
-3.35%
|
$15,596
$7.66 P/Share
|
|
Feb 17
2023
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,204
+5.94%
|
-
|
|
Feb 17
2023
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,412
-26.74%
|
$23,884
$7.66 P/Share
|
|
Feb 17
2023
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,446
+50.52%
|
-
|
|
Feb 17
2023
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
6,700
-5.25%
|
$46,900
$7.66 P/Share
|
|
Feb 17
2023
|
Thomas Andrew Crockett CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,749
+9.08%
|
-
|